Evergreening, patent challenges, and effective market life in pharmaceuticals

Journal of Health Economics

Volumn 31, Issue 2, 2012, Pages 327-339

  Hemphill, C Scott ^a   Sampat, Bhaven N ^b  

^a Columbia University ^*  (United States)

^b NONE   (United States)

Author keywords

Hatch Waxman; Innovation; Patents; Pharmaceuticals

Indexed keywords

GENERIC DRUG; OMEPRAZOLE;

DRUG; INNOVATION;

ARTICLE; DRUG APPROVAL; DRUG CONTROL; DRUG MARKETING; PATENT;

DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; PATENTS AS TOPIC; REGRESSION ANALYSIS; UNITED STATES;

EID: 84858112010     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2012.01.004     Document Type: Article

References (30)

1. Berndt E., Mortimer R., Bhattacharjya A., Parece A., Tuttle E. Authorized generic drugs, price competition and consumers' welfare. Health Affairs 2007, 26:790-799.
2. Berndt, E., Mortimer, R., Parece, A., 2007b. Do authorized generic drugs deter Paragraph IV certifications? Recent evidence. Unpublished working paper. Analysis Group, Cambridge, MA.
3. Branstetter, L., Chatterjee, C., Higgins, M., 2011. Regulation and welfare: evidence from Paragraph IV generic entry in the pharmaceutical industry. NBER working paper 17188.
4. Danzon, P., Furukawa, M., 2011. Cross-national evidence on generic pharmaceuticals: pharmacy vs. physician-driven markets. NBER working paper 17226.
5. Department of Veterans Affairs National Formulary 2011, http://www.pbm.va.gov/NationalFormulary.aspx.
6. Engelberg A., Kesselheim A., Avorn J. Balancing innovation, access, and profits-market exclusivity for biologics. New England Journal of Medicine 2009, 361:1917-1919.
7. Federal Trade Commission Generic Drug Entry Prior to Patent Expiration 2002.
8. Filson D., Oweis A. The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry. Journal of Health Economics 2010, 29:575-584.
9. Food and Drug Administration First-Time Generic Drug Approvals 2011, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ANDAGenericDrugApprovals/ucm050527.htm.
10. Food and Drug Administration Approved Drug Products with Therapeutic Equivalence 2011, http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.
11. Food and Drug Administration Drugs@FDA 2011, http://www.accessdata.fda.gov/scripts/cder/drugsatfda.
12. Food and Drug Administration Paragraph IV Patent Certifications 2011, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154350.pdf.
13. Frank R. The ongoing regulation of generic drugs. New England Journal of Medicine 2007, 357:1993-1996.
14. Goldman D., Lakdawalla D., Malkin J., Romley J., Philipson T. The benefits from giving makers of conventional " small molecule" drugs longer exclusivity over clinical trial data. Health Affairs 2011, 30:84-90.
15. Grabowski H., Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics 2007, 28:491-502.
16. Grabowski H., Moe J. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention. Cancer Prevention Research 2008, 1:84-90.
17. Grabowski H., Vernon J. Longer patents for increased generic competition in the U.S.: the Waxman-Hatch Act after one decade. Pharmacoeconomics 1996, 10:110-123.
18. Hemphill C.S., Sampat B.N. When do generics challenge drug patents?. Journal of Empirical Legal Studies 2011, 8:613-649.
19. Higgins M., Graham S. Balancing innovation and access: patent challenges tip the scales. Science 2009, 326:370-371.
20. Huskamp H., Donohue J., Koss C., Berndt E., Frank R. Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics 2008, 26:603-616.
21. IMS Institute for Healthcare Informatics The Use of Medicines in the United States: Review of 2010 2011.
22. Jaffe A., Lerner J. Innovation and Its Discontents: How Our Broken Patent System Is Endangering Innovation and Progress, and What to Do About It 2004, Princeton University Press, Princeton, NJ.
23. Kesselheim A., Avorn J. Biomedical patents and the public's health: is there a role for eminent domain?. Journal of the American Medical Association 2006, 295:434-437.
24. Lemley M. Rational ignorance at the Patent Office. Northwestern University Law Review 2001, 95:1495-1532.
25. National Academy of Sciences, National Academy of Engineering, Institute of Medicine Rising Above the Gathering Storm: Energizing and Employing America for a Brighter Economic Future 2007, National Academies Press, Washington.
26. National Institute for Health Care Management (NIHCM) Changing Patterns of Pharmaceutical Innovation 2002.
27. Panattoni L. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. Journal of Health Economics 2011, 30:126-145.
28. Roin B. Unpatentable drugs and the standards of patentability. Texas Law Review 2009, 87:503-570.
29. Thomas J. Pharmaceutical Patent Law 2005, BNA Books, Arlington, VA.
30. Wooldridge J. Econometric Analysis of Cross Section and Panel Data 2002, MIT Press, Cambridge, MA.